Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission

SK Sarin, M Kumar, M Eslam, J George… - The lancet …, 2020 - thelancet.com
Summary The Asia-Pacific region is home to more than half of the global population and
accounted for 62· 6% of global deaths due to liver diseases in 2015. 54· 3% of global deaths …

Hepatitis C treatment as prevention: evidence, feasibility, and challenges

B Hajarizadeh, J Grebely, M Martinello… - The lancet …, 2016 - thelancet.com
The advent of interferon-free direct-acting antiviral therapy for hepatitis C virus (HCV)
infection has heightened discussion of treatment as prevention. Rapid scale-up in many …

Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia

M Alavi, MG Law, H Valerio, J Grebely, J Amin… - Journal of …, 2019 - Elsevier
Background & Aims Population-level evidence for the impact of direct-acting antiviral (DAA)
therapy on hepatitis C virus (HCV)-related disease burden is lacking. We aimed to evaluate …

The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals

SR Bartlett, A Yu, N Chapinal, C Rossi, Z Butt… - Liver …, 2019 - Wiley Online Library
Background Population‐level monitoring of hepatitis C virus (HCV) infected people across
cascades of care identifies gaps in access and engagement in care and treatment. We …

Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia

J Iversen, J Grebely, B Catlett, P Cunningham… - International Journal of …, 2017 - Elsevier
Abstract Background Hepatitis C virus (HCV) infection is endemic among people who inject
drugs (PWID) globally. Despite high prevalence, treatment uptake is low, with cumulative …

The population level cascade of care for hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC-HTC)

NZ Janjua, M Kuo, A Yu, M Alvarez, S Wong, D Cook… - …, 2016 - thelancet.com
Background Population-level monitoring of hepatitis C virus (HCV) infected people across
the cascade of care identifies gaps in access and engagement in care and treatment. We …

[PDF][PDF] Australian recommendations for the management of hepatitis C virus infection: a consensus statement (September 2018)

Hepatitis C Virus Infection Consensus Statement … - 2018 - research.monash.edu
Chronic hepatitis C virus (HCV) infection is a major public health challenge for Australia,
affecting about 200 000 people who are at risk of progressive liver fibrosis leading to …

Uptake of direct‐acting antiviral treatment for chronic hepatitis C in Australia

B Hajarizadeh, J Grebely, GV Matthews… - Journal of viral …, 2018 - Wiley Online Library
A government‐funded interferon‐free direct‐acting antiviral (DAA) treatment programme for
chronic hepatitis C virus (HCV) infection has been available in Australia since March 2016 …

Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia

S Bajis, L Maher, C Treloar, B Hajarizadeh… - International Journal of …, 2018 - Elsevier
Background Uptake of hepatitis C virus (HCV) testing remains inadequate globally.
Simplified point-of-care tests should enhance HCV diagnosis and elimination. We aimed to …

Elimination of hepatitis C virus in Australia: laying the foundation

GJ Dore, B Hajarizadeh - Infectious Disease Clinics, 2018 - id.theclinics.com
The development of direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV)
infection is one of the great advances in clinical medicine in recent decades. Involving …